Alibaba updates open-source Qwen3 models to support AI deployment on Apple devices
Advertisement
In a Monday post on
social media platform
X , the Qwen team of Alibaba's
cloud computing unit said it launched open-source Qwen3 models optimised for Apple's MLX framework for machine learning. Alibaba owns the South China Morning Post.
The MLX framework is intended to be user-friendly, but still efficient in training and deploying AI models on Apple's silicon hardware. It has seen growing adoption among developers within the Apple ecosystem.
Open source gives public access to a software program's source code, allowing third-party developers to modify or share its design, fix broken links or scale up its capabilities.
This latest development appears to reflect Apple's efforts to expand the availability of its Apple Intelligence suite to mainland China. Under Chinese rules, any models that are part of Apple Intelligence would need regulatory approval for public release in the country.
Advertisement
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
26 minutes ago
- South China Morning Post
MingMed seeks Hong Kong listing to fund research and launch Botox alternative
MingMed Biotechnology is seeking a Hong Kong listing this year to raise funds to research and market a genetically engineered alternative to Botox in China. The drug developer, based in the Nansha district of Guangzhou, said it would set up an incubation centre in the Hong Kong Science and Technology Park in the third quarter. 'Hong Kong has many good universities and research institutes, but it [does not have] a lot of innovative biotech firms,' said MingMed CEO Zhang Yan in an interview on Friday. 'We aim to [turn] early-stage research discoveries at the city's universities into commercial products.' He said Hong Kong was a good platform for fundraising , early-stage drug research and global commercialisation, while Nansha was an ideal location for research and manufacturing. MingMed has raised 1.75 billion yuan (US$243.7 million) from multiple private fundraisings, Zhang said, adding that its largest institutional investor was Beijing-based Gaorong Ventures. The company filed a Hong Kong listing application in 2022, but let it lapse due to unfavourable global market conditions for biotech stocks, he said. Last year, MingMed completed a late-stage, phase-three clinical trial on a genetically manipulated alternative to Botox, which is used to reduce wrinkles. Botox is made from a naturally occurring botulinum toxin, a protein produced by a bacterium. Genetically engineered products could lower production costs and enhance product safety, Zhang said.
South China Morning Post
an hour ago
- South China Morning Post
China condemns US ‘malign influence' over Panama's plan to replace Huawei towers
Following a US announcement of a project in Panama to replace communications towers installed by Chinese telecoms giant Huawei Technologies, Beijing has condemned what it calls Washington's 'malign influence' in Latin America. Chinese Foreign Ministry spokesman Guo Jiakun said on Monday that the region was 'not the backyard of anyone' and accused the US of 'politicising economic, trade and scientific and technological issues'. He rejected US claims that Huawei's equipment posed any national security threat and said that China's dealings with countries in Latin America and the Caribbean were built on 'mutual respect'. The statement was a response to an announcement by the US embassy in Panama promoting a new US$8 million initiative to replace Huawei telecoms equipment with 'secure American technology' at 13 sites in the country. Nor was China alone in its discontent. Last week, Panamanian President José Raúl Mulino spoke at length about liberties he said the US embassy had taken in announcing the project. Developed in coordination with Panama's Ministry of Public Security, the plan includes the installation of seven new towers across four provinces.
South China Morning Post
an hour ago
- South China Morning Post
Hong Kong's CK Hutchison ports sale on thin ice amid US-China tensions: analysts
The US$23 billion sale of global port stakes by Hong Kong's CK Hutchison could be subject to substantial changes if it is not already on the verge of collapse, with Chinese and Panamanian authorities possibly rejecting the terms, legal and logistics experts have said ahead of the deal's deadline for exclusive negotiation. Their analysis followed national security and anti-monopoly concerns cited by both countries, with a recent news report suggesting that a state-owned shipping company was now involved in the negotiation to ease Beijing's concerns. The deal , which includes the Balboa and Cristobal ports at both ends of the Panama Canal, was caught in the crossfire of geopolitical tensions between the United States and China just weeks before a crucial July 27 exclusive negotiation deadline. The transaction involves CK Hutchison Holdings selling stakes in 43 ports to a consortium led by Terminal Investment Limited, an affiliate of the world's largest container line MSC, and US asset management giant BlackRock and Global Infrastructure Partners. 'The deal regarding price, due diligence and financing is basically done. What remains are the signoffs from the Panamanian and mainland authorities,' said Surinder Brrar, a professor of practice in global shipping and logistics at Polytechnic University. He described these approvals as 'big hurdles' that could derail the entire transaction if not surmounted.
